FGFR2 and cholangiocarcinoma: Therefore, at the time of writing, the sponsor intends to halt the ongoing phase III PROOF-301 (NCT03773302), in which infigratinib is evaluated as a potential first-line treatment in advanced or inoperable cholangiocarcinoma harboring FGFR2 gene fusions or translocations [32].